64 results about "Anxiolytic" patented technology

A pain relief lollipop comprises a candy matrix comprising (a) an opioid agonist, (b) an N-methyl-D-aspartate receptor antagonist different from the opioid agonist, (c) gabapentin, or a pharmaceutically acceptable salt thereof, and, optionally, a muscle relaxant, sedative, anxiolytic, and/or antidepressant. A patient can self-administer small amounts of the pain relief drug as needed by simply licking or sucking on the lollipop in response to his subjective experience of pain.

An anxiolytic drug of the invention comprises an orexin receptor antagonist, a pharmacologically acceptable salt thereof, or a solvate thereof as an active ingredient. A method for screening a compound having an anxiolytic action of the invention comprises a step of using orexin-A.

A pharmaceutical composition comprising an .alpha.3.beta.4 nicotinic receptor antagonist effective to diminish the brain-derived feeling of pleasure due to increased dopamine in the pleasure-reward center of the brain typically associated with administration of an opioid agonist analgesic, a muscle relaxant, an anti-seizure medication, an anxiolytic drug, an amphetamine, a central nervous system stimulant, a tetrahydrocannabinol or that associated with an otherwise pleasurable or self-reinforcing behavior.

Anxiety disorders, such as panic disorder, agoraphobia, obsessive-compulsive disorder, social phobia, post-traumatic stress disorder, generalized anxiety disorder, specific phobia, or the like, are treated by administering an effective amount of at least one adenosine A_2A receptor antagonist to a patient in need thereof, optionally in combination with an anxiolytic(s) other than the adenosine A_2A receptor antagonist.

The present invention is a method for the treatment of anxiety and related disorders comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I) and formula (II) as herein defined. The present invention is directed to a method for the treatment of anxiety and related disorders, which includes mono-therapy and alternatively, co-therapy with at least one anxiolytic.

The invention discloses N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazole-[1,5-α]-pyrimidin-7-yl}phenyl)acetamide (compound ( 1)), and their use as sedative-hypnotics, anxiolytics, anticonvulsants and skeletal muscle relaxants. At the same time, methods for preparing the substance and related compositions are also disclosed, especially for the treatment of insomnia. And provides the exceptional physical and thermal stability possessed by the Form I polymorph. Type II polymorphs are also contemplated.

The invention provides to an anti-anxiety medicine by using a rheum officinate root extract as an active ingredient. The anti-anxiety medicine uses the rheum officinate root extract as the active ingredient and can be made into various oral administration formulations such as tablet, granules, capsule, oral liquor, etc.; other components and supplementary materials can be added to form a compound preparation; and the anti-anxiety medicine has evident anti-anxiety effect and can be used for health and treatment of anxiety disorder. Moreover, the invention further provides health food prepared from the rheum officinate root extract and food additives, and preparation methods of the medicine and the food.

The present invention comprises compositions comprising combinations of kava extract compositions in combination with one or more anxiolytics and methods for treating conditions related to the various anxiety disorders comprising administering the compositions of the present invention. The invention further provides methods for enhancing the therapeutic activity of an anxiolytic comprising administering the anxiolyitc in combination with extract of Piper methysticin.

Methods and pharmaceutical compositions comprising a low dose of a farnesyl transferase inhibitor useful in the treatment of proteinopathies are provided. These low doses are below the doses used in oncological treatments for which these compounds were initially designed. The treatment includes administering to a subject an amount of a farnesyl transferase inhibitor, wherein the amount administered is sufficient to cause an improvement in mitochondrial health in said subject. Treatments in accordance with the present invention may also include an acetylcholinesterase inhibitor, an activator of neurotrophic receptors, an NMDA anatagonist, an amyloid deposit inhibitor, an antipsychotic agent, an antidepressant, an anxiolytic, or an antioxidant.

The invention includes methods for treating tobacco addiction and nicotine addiction of patients, alleviating nicotine withdrawal symptoms, providing or promoting curative effect of smoking cessation treatment and as long-term smoking cessation maintenance treatment. The invention also relates to a pharmaceutical composition comprising a nicotine receptor antagonist and an antidepressant or an anxiolytic. A specific combination of drugs (mecamylamine hydrochloride and bupropion hydrochloride) and a pharmaceutical composition formed by combining mecamylamine with certain types of drugs (such as anxiolytics and antidepressants) are disclosed. These compositions are also contemplated for use in the treatment of cocaine addiction and the treatment of alcohol dependence.

Methods and pharmaceutical compositions comprising a low dose of a farnesyl transferase inhibitor useful in the treatment of proteinopathies and mitochondrial disorders are provided. These low doses are below the doses used in oncological treatments for which these compounds were initially designed. The treatment includes administering to a subject an amount of a farnesyl transferase inhibitor, wherein the amount administered is sufficient to stimulate mitophagy in said subject. Treatments in accordance with the present invention may also include an acetylcholinesterase inhibitor, an activator of neurotrophic receptors, an NMDA anatagonist, an amyloid deposit inhibitor, an antipsychotic agent, an antidepressant, an anxiolytic, or an antioxidant.

Methods and pharmaceutical compositions comprising a low dose of a farnesyl transferase inhibitor useful in the treatment of proteinopathies are provided. These low doses are below the doses used in oncological treatments for which these compounds were initially designed. The treatment includes administering to a subject in need thereof a therapeutically effective amount of a farnesyl transferase inhibitor, wherein the amount is effective to inhibit the farnesylation of a non-Ras FTase substrate involved in the autophagy pathway without substantially affecting the farnesylation of Ras or other oncology related substrates. Treatments in accordance with the present invention may also include an acetylcholinesterase inhibitor, an activator of neurotrophic receptors, an NMDA antagonist, an amyloid deposit inhibitor, an antipsychotic agent, an antidepressant, an anxiolytic, or an antioxidant.

The invention relates to application of coptis and alkaloid thereof in preparation of an anti-anxiety medicament. The problem that the coptis or the alkaloid is applied in preparation of the anti-anxiety medicament can be effectively solved. The invention adopts the technical scheme that: the coptis is decocted into coptis decoction by adding water, or the coptis is extracted by using ethanol, then coptis alkaloid is prepared by using water bath, and the coptis water bath fluid or the coptis alkaloid is subjected to mouse cross maze or light and dark box passing experiments; and the experiment results show that the coptis and the alkaloid thereof have anti-anxiety effect. The application can expand the medicinal value of the coptis, and is an innovation on the anti-anxiety medicament.

The invention relates to a family of hexapeptide compounds exhibiting activity with regard to the ORL-1 receptor. The compounds share a general formula of Arg-Tyr-Tyr-Arg-Trp-Arg, and may be constructed having modifications or substitutions at any position, and may include modifications of the amino- and carboxy-termini of the hexapeptide. These compounds include agents exhibiting agonist activity and antagonist activity when exposed to the human ORL-1 receptor. As such, the hexapeptides may be useful as analgesics, anxiolytics, diuretics, and anti-cancer agents.

This invention provides a method for identifying a small molecule as an antidepressant, a method for identifying a small molecule as an anxiolytic, and a method for identifying a small molecule as able to increase dendritic arborization, decrease expression of an immaturity marker, increase expression of a maturity marker, or enhance artificial cerebrospinal fluid-type long-term potentiation in central nervous system. This invention also provides a transgenic mouse model for SSRI-non-responders.

The invention belongs to the field of drugs or health products and particularly relates to an application of NADPH in preparation of anti-anxiety drugs. The research finds that the NADPH is capable of significantly improving the exploration interest, significantly reducing the anxiety level of a rat and reversing anxiety behaviors caused by chronic stress. The results show that the NADPH has an anti-anxiety effect, and can be used as a potential drug for preventing or treating generalized anxiety disorder.

Pharmaceutical compositions for preventing or treating anxiety, comprising betulinic acid or derivatives thereof are provided. Methods for preventing or treating anxiety with betulinic acid or derivatives thereof are also provided. The invention further provides betulinic-acid containing preparations of plants of the family Marcgraviaceae having anxiolytic activity and methods for making such extracts and using them to prevent or treat anxiety in a subject.